share_log

PharmaCielo Makes First Shipment Of Cannabinoid Products To Mexican Joint Venture Partner

PharmaCielo Makes First Shipment Of Cannabinoid Products To Mexican Joint Venture Partner

PharmaCielo向墨西哥合資夥伴發運第一批大麻產品
Benzinga Real-time News ·  2022/08/04 09:54

PharmaCielo Ltd. (OTCQX:PCLOF) (TSXV:PCLO) made its first shipment of cannabinoid products to its Mexican joint venture PharmaCielo S.A. de C.V. ("PharmaCielo Mexico").

PharmaCielo Ltd.(OTCQX:PCLOF)(多倫多證券交易所股票代碼:PCLO)第一批大麻素產品至ITS墨西哥合資企業PharmaCielo S.A.de C.V. ("墨西哥PharmaCielo").

The company's joint partner in PharmaCielo Mexico is MINO Labs S.A. de C.V., which is a specialty pharmaceutical company and medical supply distributor based in Mexico. PharmaCielo Mexico has arranged for this initial shipment to support the product development efforts of a potential customer, which is in the process of developing cannabinoid-based phytotherapeutic products for the Mexican market.

該公司在墨西哥PharmaCielo的聯合合作伙伴是Mino Labs S.A.de C.V.,這是一家總部位於墨西哥的專業製藥公司和醫療用品分銷商。PharmaCielo墨西哥公司已經安排了第一批貨物,以支持一個潛在客户的產品開發工作,該客户正在為墨西哥市場開發基於大麻素的植物治療產品。

Bill Petron, CEO of PharmaCielo, stated, "The Mexican market represents a large, near and mid-term opportunity for PharmaCielo, and we are proud to export cannabinoids in support of the development of products for the medicinal market. PharmaCielo Mexico is positioned to be a preferred supplier in the country, backed by PharmaCielo's proven ability to supply extracts and flower products at scale, with consistent quality and value, and MINO Labs' successful track record in the Mexican market. PharmaCielo's global sales pipeline continues to build, and we expect 2022 and 2023 to be pivotal years for growth and value creation for shareholders, as we continue to execute our strategy."

比爾·彼得龍PharmaCielo首席執行官表示:“墨西哥市場對PharmaCielo來説是一個巨大的近期和中期機遇,我們為出口大麻類藥物以支持醫藥市場產品的開發而感到自豪。PharmaCielo墨西哥公司已被證明有能力大規模供應提取物和花卉產品,具有穩定的質量和價值,而且Mino Labs在墨西哥市場的成功記錄也是我們的支持,PharmaCielo墨西哥公司將成為墨西哥的首選供應商。PharmaCielo公司的全球銷售渠道仍在建設中,我們預計2022年和2023年將是股東增長和價值創造的關鍵年份,因為我們繼續執行我們的戰略。”

Manuel Cosme Odabachian, CEO of Mino Labs, stated, "MINO Labs has been a leader in the Mexican specialty pharmaceutical distribution sector for more than 20 years. As the country continues to move towards legalization for medical use, we are seeing significant interest from our existing customer base in taking product for pharmaceutical product development. Mexico is a large potential market, and we fully expect the combination of Mino Labs' long track record of selling into the specialty pharma sector in the country, and PharmaCielo's ability to produce pharma-grade product consistently, will be a winning combination as demand continues to grow."

曼努埃爾·科斯梅·奧達巴契亞20多年來,Mino Labs一直是墨西哥特種藥品分銷領域的領先者。隨着墨西哥繼續走向醫療用途合法化,我們看到我們現有的客户羣對採用藥品產品開發的產品產生了巨大的興趣。墨西哥是一個巨大的潛在市場,我們完全預計,Mino Labs在該國特種製藥部門銷售的長期記錄與Pharmacielo持續生產藥級產品的能力的結合,將是隨着需求的持續增長而取得成功的組合。

Photo by CRYSTALWEED cannabis on Unsplash

結晶器大麻在Unspash上的照片

Related News

相關新聞

Strategic Cannabis Execs Making Changes At Companies You Know: PharmaCielo, Willow Industries, Delta 9 & More

戰略大麻高管在你知道的公司做出改變:PharmaCielo、Willow Industries、Delta 9等

PharmaCielo Signs Sales Agreement With Brazilian Phyto-Therapeutic Company

PharmaCielo與巴西植物治療公司簽署銷售協議

PharmaCielo Ships CBD Full Spectrum Oil To A Brazilian Pharmaceutical Company

PharmaCielo向巴西一家制藥公司運送CBD全光譜油

 

Â

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論